Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement - ScienceDirect
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease - Journal of Pharmaceutical Sciences
Tau Clinical Trials – What can be learned from failure? - Etap Lab
Targeting tau: Clinical trials and novel therapeutic approaches - ScienceDirect
Tau-targeting therapies for Alzheimer disease. - Abstract - Europe PMC
Tau Antibody Structure Reveals a Molecular Switch Defining a Pathological Conformation of the Tau Protein | Scientific Reports
International Alzheimer's clinical trial to test tau drugs – Washington University School of Medicine in St. Louis
Tau Polyclonal Antibody
Anti-Tau Antibodies: Hitting the Target - ScienceDirect
IJMS | Free Full-Text | Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies | HTML
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease - ScienceDirect
Frontiers | Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead | Neuroscience
Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies | npj Vaccines
Common features of anti-amyloid beta (Aβ) and anti-tau antibodies. Both... | Download Scientific Diagram
Vaccination strategies in tauopathies and synucleinopathies - Braczynski - 2017 - Journal of Neurochemistry - Wiley Online Library
Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models - Journal of Biological Chemistry
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES • The Journal of Prevention of Alzheimer's Disease
More Tau Antibodies Bid Adieu; Semorinemab Keeps Foot in Door | ALZFORUM
FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI'S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU
ANTI-TAU TRIALS FOR ALZHEIMER'S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE • The Journal of Prevention of Alzheimer's Disease
ARISE study: Study Design and Baseline Characteristics for a Phase 2 Trial of the Anti-Tau Antibody ABBV-8E12 in Progressive Supranuclear Palsy - MDS Abstracts
Advances and considerations in AD tau-targeted immunotherapy - ScienceDirect
Frontiers | Targeting Tau to Treat Clinical Features of Huntington's Disease | Neurology
AC Immune's Tau Vaccine for Alzheimer's Advanced into Phase Ib/II Clinical Trials | BioSpace
AC Immune Reports Top Line Results from TAURIEL Phase 2
